Monte Rosa Therapeutics Shares Outstanding History (GLUE)
Monte Rosa Therapeutics reported 65.5M shares outstanding at the end of fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 65.5M | 4.0M | +6.56% |
| 2024 | 2024-12-31 | 61.5M | 11.4M | +22.67% |
| 2023 | 2023-12-31 | 50.1M | 816,702 | +1.66% |
| 2022 | 2022-12-31 | 49.3M | 2.8M | +5.99% |
| 2021 | 2021-12-31 | 46.5M | 44.9M | +2660.90% |
| 2020 | 2020-12-31 | 1.7M | — | — |
Monte Rosa Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 85.2M | 23.5M | +38.09% |
| Q1 2026 | 2026-03-31 | 84.3M | 22.8M | +37.09% |
| Q4 2025 | 2025-12-31 | 65.5M | 4.0M | +6.56% |
| Q3 2025 | 2025-09-30 | 61.8M | 412,755 | +0.67% |
| Q2 2025 | 2025-06-30 | 61.7M | 389,067 | +0.63% |
| Q1 2025 | 2025-03-31 | 61.5M | 11.3M | +22.53% |
| Q4 2024 | 2024-12-31 | 61.5M | 11.4M | +22.67% |
| Q3 2024 | 2024-09-30 | 61.4M | 11.3M | +22.59% |
| Q2 2024 | 2024-06-30 | 61.3M | 11.7M | +23.66% |
| Q1 2024 | 2024-03-31 | 50.2M | 839,320 | +1.70% |
| Q4 2023 | 2023-12-31 | 50.1M | 816,702 | +1.66% |
| Q3 2023 | 2023-09-30 | 50.1M | 1.7M | +3.50% |
| Q2 2023 | 2023-06-30 | 49.6M | 2.9M | +6.23% |
| Q1 2023 | 2023-03-31 | 49.4M | 2.7M | +5.86% |
| Q4 2022 | 2022-12-31 | 49.3M | 2.8M | +5.99% |
| Q3 2022 | 2022-09-30 | 48.4M | 1.9M | +4.06% |
| Q2 2022 | 2022-06-30 | 46.7M | 2.1M | +4.67% |
| Q1 2022 | 2022-03-31 | 46.6M | 44.9M | +2666.52% |
| Q4 2021 | 2021-12-31 | 46.5M | — | — |
| Q3 2021 | 2021-09-30 | 46.5M | — | — |
| Q2 2021 | 2021-06-30 | 44.6M | — | — |
| Q4 2020 | 2020-12-31 | 1.7M | — | — |
Monte Rosa Therapeutics shares outstanding trends
Over the last five reported fiscal years, Monte Rosa Therapeutics's shares outstanding moved from 1.7M to 65.5M, a change of 63.9M. The latest reported quarter, Q2 2026, shows 85.2M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics filings at SEC.gov ↗